Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Operating Leases (2019 - 2025)

Historic Operating Leases for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $138.7 million.

  • Beam Therapeutics' Operating Leases fell 697.18% to $138.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.7 million, marking a year-over-year decrease of 697.18%. This contributed to the annual value of $148.0 million for FY2024, which is 747.6% down from last year.
  • Latest data reveals that Beam Therapeutics reported Operating Leases of $138.7 million as of Q3 2025, which was down 697.18% from $141.9 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Operating Leases registered a high of $168.6 million during Q4 2022, and its lowest value of $125.8 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Leases was $149.1 million (2024), whereas its average is $149.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 45909.28% in 2021, then crashed by 747.6% in 2024.
  • Over the past 5 years, Beam Therapeutics' Operating Leases (Quarter) stood at $134.8 million in 2021, then rose by 25.08% to $168.6 million in 2022, then decreased by 5.17% to $159.9 million in 2023, then fell by 7.48% to $148.0 million in 2024, then dropped by 6.23% to $138.7 million in 2025.
  • Its Operating Leases was $138.7 million in Q3 2025, compared to $141.9 million in Q2 2025 and $144.9 million in Q1 2025.